MX2019006880A - Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades. - Google Patents

Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades.

Info

Publication number
MX2019006880A
MX2019006880A MX2019006880A MX2019006880A MX2019006880A MX 2019006880 A MX2019006880 A MX 2019006880A MX 2019006880 A MX2019006880 A MX 2019006880A MX 2019006880 A MX2019006880 A MX 2019006880A MX 2019006880 A MX2019006880 A MX 2019006880A
Authority
MX
Mexico
Prior art keywords
compounds
group
glutaminyl cyclase
diseases
treatment
Prior art date
Application number
MX2019006880A
Other languages
English (en)
Inventor
Evgenievich Nebolsin Vladimir
Alexandrovna Kromova Tatyana
Vladimirovna RYDLOVSKAYA Anastasia
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2017118350A external-priority patent/RU2665633C1/ru
Priority claimed from RU2017137615A external-priority patent/RU2662559C1/ru
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Publication of MX2019006880A publication Critical patent/MX2019006880A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/02Aminoacyltransferases (2.3.2)
    • C12Y203/02005Glutaminyl-peptide cyclotransferase (2.3.2.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a la quimica de sustancias organicas, farmacologia y medicina, y se relaciona al tratamiento de enfermedades asociadas y con la actividad aberrante de celulas del sistema inmune, mas particularmente para el tratamiento de enfermedades del pulmon, del tracto respiratorio y abdominales, malestar por radiacion y sindrome de dolor, y tambien otras enfermedades al utilizar compuestos de formula (A) [ver fórmula (A)] en donde R1 es un grupo -C(O)-R2-C(O)- o -R2-C(O)-, donde R2 es un grupo -(CH2)n- opcionalmente sustituido con uno o dos alquilos de C1-C6, o fenilo, n es un entero de 0 a 4; en donde los compuestos se seleccionan del grupo que consiste del grupo de compuestos como se establece en la descripcion; estos compuestos, asi como las sales farmaceuticamente aceptables de los mismos, son altamente eficaces para inhibir la glutaminil ciclasa, que esta involucrada, en particular, en procesos de modificacion post-traduccional de quimiocinas y quimiotaxis de monocitos, macrofagos y otras celulas del sistema inmune; esta invencion tambien se refiere a composiciones farmaceuticas que comprenden una cantidad terapeuticamente eficaz de los compuestos de formula (A) como se definieron anteriormente.
MX2019006880A 2017-05-26 2018-05-24 Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades. MX2019006880A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2017118350A RU2665633C1 (ru) 2017-05-26 2017-05-26 Новый ингибитор глутаминилциклаз и его применение
RU2017137615A RU2662559C1 (ru) 2017-10-27 2017-10-27 Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей
PCT/RU2018/050058 WO2018217139A1 (ru) 2017-05-26 2018-05-24 Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний

Publications (1)

Publication Number Publication Date
MX2019006880A true MX2019006880A (es) 2019-08-01

Family

ID=64396616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006880A MX2019006880A (es) 2017-05-26 2018-05-24 Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades.

Country Status (13)

Country Link
US (2) US11845740B2 (es)
EP (2) EP3632433A4 (es)
JP (2) JP7293114B2 (es)
KR (3) KR20200010164A (es)
CN (3) CN118141807A (es)
AU (1) AU2018273483B2 (es)
BR (1) BR112019012597A2 (es)
CA (1) CA3046196A1 (es)
IL (1) IL267077B (es)
MX (1) MX2019006880A (es)
UA (1) UA124636C2 (es)
WO (1) WO2018217139A1 (es)
ZA (1) ZA201903828B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2647438C2 (ru) * 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
RU2685277C1 (ru) * 2018-05-24 2019-04-17 Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных
CN114874186B (zh) * 2022-05-16 2023-07-11 深圳大学 一种谷氨酰胺酰基环化酶同工酶抑制剂及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
GB2447017A (en) * 2007-03-01 2008-09-03 Probiodrug Ag New use for inhibitors of glutaminyl peptide cyclotransferinase
EA201200111A1 (ru) 2007-03-01 2012-06-29 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
RU2665688C2 (ru) 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
CA2913914C (en) 2013-05-28 2018-03-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
CN106231901A (zh) 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
US9663491B2 (en) 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
RU2647438C2 (ru) 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
DE102015011780A1 (de) 2015-09-16 2017-03-16 Hochschule Anhalt Neue Glutaminylcyclase-lnhibitoren
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Also Published As

Publication number Publication date
JP2023071720A (ja) 2023-05-23
AU2018273483B2 (en) 2024-06-13
WO2018217139A1 (ru) 2018-11-29
UA124636C2 (uk) 2021-10-20
KR20240035919A (ko) 2024-03-18
CA3046196A1 (en) 2018-11-29
EP3632433A4 (en) 2021-03-03
CN110087650B (zh) 2024-03-22
AU2018273483A1 (en) 2019-06-20
IL267077A (en) 2019-10-31
US20240116898A1 (en) 2024-04-11
ZA201903828B (en) 2023-02-22
BR112019012597A2 (pt) 2019-11-19
EP4335509A2 (en) 2024-03-13
CN110087650A (zh) 2019-08-02
JP2021533078A (ja) 2021-12-02
CN118141807A (zh) 2024-06-07
KR20240035920A (ko) 2024-03-18
KR20200010164A (ko) 2020-01-30
CN118141806A (zh) 2024-06-07
EP4335509A3 (en) 2024-06-05
WO2018217139A4 (ru) 2018-12-20
IL267077B (en) 2022-07-01
US11845740B2 (en) 2023-12-19
EP3632433A1 (en) 2020-04-08
US20200087285A1 (en) 2020-03-19
JP7293114B2 (ja) 2023-06-19

Similar Documents

Publication Publication Date Title
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
PH12021550310A1 (en) Novel sulfonamideurea compounds
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CR20230310A (es) Inhibidores de prmt5
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2020011501A (es) Compuestos novedosos.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
EA201100305A1 (ru) Лечение респираторных заболеваний
MX2019006880A (es) Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
EA202192894A1 (ru) Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
TW200736203A (en) New pleuromutilin derivative and its use
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
NO20055754L (no) Kolkisosidanaloger